Publications
Articles
1. Gauthier SA, Glanz BI, Mandel M, Tsagkaropoulos A, Neema M, Stankiewicz J, et al. Incidence and Factors Associated with Treatment Failure in the CLIMB Multiple Sclerosis Cohort Study Jour. Neurol. Sciences. in press
2. Gauthier SA, Berger AM, Liptak Z, Duan Y, Egorova S, Buckle GJ, Glanz BI, Khoury SJ, Bakshi R, Weiner HL, Guttmann CRG. Benign MS is characterized by a lower rate of brain atrophy as compared to early MS. Arch. Neurol. 2009 Feb;66(2):234-7
3. Bakshi R, Neema M, Healy B, Liptak Z, Betensky R, Buckle G, Gauthier, SA et al. Magnetic Resonance Disease Severity Score Predicts Clinical Progression in Multiple Sclerosis. Arch. Neurol. 2008 Nov;65(11):1449-53
4. Gauthier SA, Mandel M, Guttmann CRG, Glanz BI, Khoury SJ, Betensky RA, Weiner, HL Predicting Short-term Disability in Multiple Sclerosis. Neurology. 2007 Jun 12;68 (24):2059-65
5. Mandel M, Gauthier SA, Guttman CRG, Weiner HL, Betensky R. Estimating Time to Event from Longitudinal Categorical Data: An Analysis of Multiple Sclerosis Progression. Journal of the American Statistical Association. Dec 2007;102 (480):1254-1266
6. Glanz BI, Holland C, Gauthier SA, et al. Cognitive Dysfunction in Patients with Clinically Isolated Syndromes or Newly Diagnosed MS. Multiple Sclerosis; Mult Scler. 2007 Sept;13(8): 1004-10
Chapters and reviews
1. Gauthier SA, Buckle G, Weiner HL, Immunosuppressant Therapy for Multiple Sclerosis. Neurology Clinics, 2005;23:247-272.
2 .Gauthier SA, Weiner HL, Cyclophosphamide therapy for MS. The International MS Journal; 2005:12:52-58
3. Gauthier SA, Glanz BI, Mandel M, Weiner HL, A Model for the Comprehensive Investigation of a Chronic Autoimmune Disease: The Multiple Sclerosis CLIMB Study. Autoimmun
Rev 2006 Oct; 5(8):532-6
4. Gauthier SA, Weiner HL, Use of cyclophosphamide and other immunosuppressants to treat multiple sclerosis. Multiple Sclerosis Therapeutics, 3rd Edition , 2007
